Fibrosis Inflammatory Articles & Analysis
6 news found
Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023 Atopic Dermatitis Program will be delayed due to restructuring ...
ByBiomX
” About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. ...
ByBiomX
About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. ...
ByBiomX
Tarka was Vice President, Clinical Development at Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Earlier in her career, she served as Clinical Program Leader for Xarelto® (rivaroxaban) at Janssen Pharmaceuticals, where she was responsible for the design, implementation, and medical ...
(NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (“CF Foundation”). ...
ByBiomX
As such, it represents a potential step-change in the treatment of many conditions where inflammatory scarring compromises tissue function”. TIKOMED’s study, conducted at the School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, UK is the first to demonstrate that subcutaneous injections of ILB®, which has already demonstrated ...